What is Bioatla Inc (BCAB) stock price today?

Bioatla Inc (BCAB) currently trades at $4.21 per share. The stock has a market capitalization of $8.07M and a P/E ratio of —x.

Is BCAB stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Bioatla Inc has a Smart Value Score of 32/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Bioatla Inc's revenue and earnings?

Bioatla Inc has trailing twelve-month (TTM) revenue of $2.00M with profit margins of 0.00%. Earnings per share (EPS) is $-50.50.

BCAB

Bioatla Inc

NASDAQ: BCAB · HEALTHCARE · BIOTECHNOLOGY

$4.21

+4.21% today

Updated 2026-04-30

Market cap

$8.07M

P/E ratio

—

P/S ratio

4.04x

EPS (TTM)

$-50.50

Dividend yield

—

52W range

$4 – $72

Volume

1.0M

Market cap

$8.07M

P/E ratio

—

P/S ratio

4.04x

EPS (TTM)

$-50.50

Dividend yield

—

52W range

$4 – $72

Volume

1.0M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

6.3

Growth

5.0

Quality

C+

2.5

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →204 stocks currently score above 75

Price targets

Analyst target

$10.00

+137.53%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

X-Ray snapshot

Strengths

+ Revenue growth 31.60% QoQ

Risks

- Thin margins at 0.00%

- Negative free cash flow $-7.92M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$11.00M	$2.00M	$2.00M
Net income	$-105.28M	$-123.46M	$-69.78M	$-59.61M	$-9.78M
EPS	—	—	—	—	$-50.50
Free cash flow	$-90.69M	$-104.11M	$-71.94M	$-48.20M	$-7.92M
Profit margin	—	—	-634.33%	-2,980.35%	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
BCAB	$8.07M	32	6.3	2.5	5.0	5.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Bioatla Inc trades at $4.21. Our Smart Value Score of 32/100 indicates the stock is weak. TTM revenue stands at $2.00M.

Frequently asked questions

What is Bioatla Inc's stock price?

Bioatla Inc (BCAB) trades at $4.21.

Is Bioatla Inc overvalued?

Smart Value Score 32/100 (Grade F, Strong Sell).

What is the price target of Bioatla Inc (BCAB)?

The analyst target price is $10.00, representing +137.5% upside from the current price of $4.21.

What is Bioatla Inc's revenue?

TTM revenue is $2.00M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio4.04x

ROE-814.00%

Beta1.21

50D MA$7.44

200D MA$23.36

Shares out0.00B

Float0.00B

Short ratio—

Avg volume1.0M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

BCAB vs LLY →BCAB vs JNJ →BCAB vs ABBV →Stock screener →